Here they come the Bozo's from out of left field, iknightv and tmatkj are leading the charge. There will be many to follow pumping, pumping and then preaching the SKY IS FALLING. Folks its just plain time to ignore these boobs and let the real deal unfold. Its possible that these pumper/basher peaks and crashes could fade into the dark.
Jim Long and calm
Sentiment: Strong Buy
Hey Jim..I have seen your keen advise over the years...It is time to do just what you say....turn off all the bs and just wait until mid November..Time will tell!!! It seems to me that all the REAL investors have done their
due diligence have made a good case for ZLCS after 7 years in development!!! Let's hope we get good news!!!
GIVE IT A REST!. It dropped more than 2.50 in less than a month and you know where it's going soon. Oh I forgot, next month, next quarter, next year.....yeah right. You of all people riding it puppy down. You better go change yourself after this pop.
Jason Napodano did not model a big pharma partnership deal nor any expected FDA fast track options which are highly likely given opioid drug addiction, especially among service men and women. He also based future PPS estimates off the most recent low. Why low ball us? I believe the only thing Jason consistently gets right is when he repeats what management tells him: 1. There will be a reverse split. 2. The trial results will be announced mid-November to give Lincoln a chance to sell if they want. Beyond this another decade to develop a pain drug that can be tested in six-weeks? His timeline for Z160 appears to be mixed up with a cancer drug evaluating long-term mortality. Jason is talking six year before Z160 sees the light of day? Corrigan can increase the patient numbers and locations for a phase 3 and have results in no time with a Merck or Pfizer as a partner. A phase 2b takes one year, and then a phase 3 takes 5?
Sentiment: Strong Buy
Hopefully no P2B will be needed. Good results and ZLCS will quickly partner Z160 out to a BP who will run multiple P3s. P2B trial only needed if the Z160 data is not clear. P2B would be needed if there are effective dose and side effect questions remaining after we see next month's data.
Agree 100%. This article was a great example of 'damning with faint praise'. Wonder what the author's real agenda is. I'd look for Phase III(s) to initiate in Q2 2014 and filing/approval in 2015 (if breakthough drug/fast track status granted). It wouldn't surprise me if the Phase III requirement is dropped entirely, ala ACAD.